NASDAQ: GUTS
Fractyl Health Inc Stock Forecast, Predictions & Price Target

Analyst price target for GUTS

Based on 1 analyst offering 12 month price targets for Fractyl Health Inc

Min Forecast
$10.00+629.93%
Avg Forecast
$10.00+629.93%
Max Forecast
$10.00+629.93%

Should I buy or sell GUTS stock?

Based on 1 analyst offering ratings for Fractyl Health Inc.

Strong Buy
Strong Buy
1 analysts 100%
Buy
0 analysts 0%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although GUTS's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates GUTS as a "Strong Sell". Stocks with a Zen Rating of Strong Sell have had an average return of -8.02% per year. Learn More

Be the first to know when Wall Street analysts revise their GUTS stock forecasts and price targets.

GUTS stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-04-15
lockedlocked$00.00+00.00%2025-02-03

1 of 1

Forecast return on equity

Is GUTS forecast to generate an efficient return?

Company
-149.73%
Industry
80.01%
Market
61.99%
GUTS's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is GUTS forecast to generate an efficient return on assets?

Company
-39.38%
Industry
22.35%
GUTS is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

GUTS earnings per share forecast

What is GUTS's earnings per share in the next 3 years based on estimates from 2 analysts?

Avg 1 year Forecast
-$1.42
Avg 2 year Forecast
-$1.71
Avg 3 year Forecast
-$0.87

GUTS revenue forecast

What is GUTS's revenue in the next 1 years based on estimates from 1 analyst?

Avg 1 year Forecast
$12.4M+13,269.89%
GUTS's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

GUTS revenue growth forecast

How is GUTS forecast to perform vs Biotechnology companies and vs the US market?

Company
1,532.17%
Industry
152.36%
Market
10.68%
GUTS's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
GUTS's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

GUTS vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
GUTS$1.37$10.00+629.93%Strong Buy
IVVD$0.56$7.52+1,239.93%Strong Buy
JSPR$4.44$51.80+1,066.67%Buy
ACOG$4.21$20.00+375.06%Buy
IFRX$1.14$9.00+689.47%Strong Buy

Fractyl Health Stock Forecast FAQ

Is Fractyl Health Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: GUTS) stock is to Strong Buy GUTS stock.

Out of 1 analyst, 1 (100%) are recommending GUTS as a Strong Buy, 0 (0%) are recommending GUTS as a Buy, 0 (0%) are recommending GUTS as a Hold, 0 (0%) are recommending GUTS as a Sell, and 0 (0%) are recommending GUTS as a Strong Sell.

If you're new to stock investing, here's how to buy Fractyl Health stock.

What is GUTS's earnings growth forecast for 2025-2027?

(NASDAQ: GUTS) Fractyl Health's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 17.99%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 23.64%.

Fractyl Health's earnings in 2025 is -$70,431,000.On average, 2 Wall Street analysts forecast GUTS's earnings for 2025 to be -$69,466,714, with the lowest GUTS earnings forecast at -$76,804,747, and the highest GUTS earnings forecast at -$62,128,681. On average, 2 Wall Street analysts forecast GUTS's earnings for 2026 to be -$83,653,578, with the lowest GUTS earnings forecast at -$116,919,328, and the highest GUTS earnings forecast at -$50,387,828.

In 2027, GUTS is forecast to generate -$42,560,592 in earnings, with the lowest earnings forecast at -$42,560,592 and the highest earnings forecast at -$42,560,592.

What is GUTS's revenue growth forecast for 2026-2026?

(NASDAQ: GUTS) Fractyl Health's forecast annual revenue growth rate of 1,532.17% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 152.36%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.68%.

Fractyl Health's revenue in 2025 is $93,000.

In 2026, GUTS is forecast to generate $608,274,028 in revenue, with the lowest revenue forecast at $608,274,028 and the highest revenue forecast at $608,274,028.

What is GUTS's forecast return on assets (ROA) for 2025-2027?

(NASDAQ: GUTS) forecast ROA is -39.38%, which is lower than the forecast US Biotechnology industry average of 22.35%.

What is GUTS's Price Target?

According to 1 Wall Street analyst that have issued a 1 year GUTS price target, the average GUTS price target is $10.00, with the highest GUTS stock price forecast at $10.00 and the lowest GUTS stock price forecast at $10.00.

The Wall Street analyst predicted that Fractyl Health's share price could reach $10.00 by Feb 3, 2026. The average Fractyl Health stock price prediction forecasts a potential upside of 629.93% from the current GUTS share price of $1.37.

What is GUTS's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: GUTS) Fractyl Health's current Earnings Per Share (EPS) is -$1.62. On average, analysts forecast that GUTS's EPS will be -$1.42 for 2025, with the lowest EPS forecast at -$1.57, and the highest EPS forecast at -$1.27. On average, analysts forecast that GUTS's EPS will be -$1.71 for 2026, with the lowest EPS forecast at -$2.39, and the highest EPS forecast at -$1.03. In 2027, GUTS's EPS is forecast to hit -$0.87 (min: -$0.87, max: -$0.87).

What is GUTS's forecast return on equity (ROE) for 2025-2027?

(NASDAQ: GUTS) forecast ROE is -149.73%, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.